Literature DB >> 16482557

Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.

Masahiro Kobayashi1, Kenji Ikeda, Tetsuya Hosaka, Hitomi Sezaki, Takashi Someya, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Yuzo Miyakawa, Hiromitsu Kumada.   

Abstract

Natural histories of compensated cirrhosis in the Child-Pugh class A were compared between the 490 patients infected with hepatitis C virus (HCV) and 167 patients with hepatitis B virus (HBV) who were followed for more than 1 year up to 20 years without antiviral treatment. Patients with HCV were older (median age: 59 vs. 45 years), less predominantly male (59.0% vs. 76.0%), transfused more frequently (49.2% vs. 9.0%), and had higher aminotransferase as well as lower albumin levels and fewer platelets (P < 0.001 for all). Death was commoner (55.1% vs. 35.9%, P < 0.001) and hepatocellular carcinoma developed more often (53.9% vs. 28.7%, P < 0.001) in patients with HCV than HBV. In multivariate analysis, low albumin levels (hazard ratio: 1.65), alpha-fetoprotein (1.55), alcohol consumption (1.49), age >55 years (1.47), and retention of indocyanine green (1.39) were independent risk factors for the survival in patients with HCV, while male gender (4.43), age >45 years (2.24), retention of indocyanine green (2.14), hepatitis B e antigen (2.11), and low platelet counts (1.91) were in those with HBV. Chances for survival was significantly different (P < 0.001) among patients with HCV having low (number of factors: 0-1), medium (2-3), and high risks (4-5), as well as in those with HBV having low (0-1), medium (2-4), and high risks (5-6). In conclusion, survival and development of hepatocellular carcinoma, and factors for survival, are considerably different between patients with compensated cirrhosis infected with HCV and HBV, which would need to be taken into consideration in their management and planning treatment strategies. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482557     DOI: 10.1002/jmv.20562

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

1.  Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis.

Authors:  Yuko Nagaoki; Hiroshi Aikata; Tomoki Kobayashi; Takayuki Fukuhara; Keiichi Masaki; Mio Tanaka; Noriaki Naeshiro; Takashi Nakahara; Yohji Honda; Daisuke Miyaki; Tomokazu Kawaoka; Shintaro Takaki; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Hideyuki Hyogo; Yoshiiku Kawakami; Shoichi Takahashi; Hidenori Ochi; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2012-10-05       Impact factor: 7.527

2.  Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients.

Authors:  Kazunari Sasaki; Junichi Shindoh; Yujiro Nishioka; Georgios A Margonis; Toshitaka Sugawara; Nikolaos Andreatos; Masaji Hashimoto; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-01-03       Impact factor: 3.452

3.  Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma.

Authors:  Qian Zhu; Jing Li; Jian-Jun Yan; Liang Huang; Meng-Chao Wu; Yi-Qun Yan
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 4.  Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 5.  Nutrition and exercise in the management of liver cirrhosis.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study.

Authors:  Jing Li; Liang Huang; Cai-Feng Liu; Jie Cao; Jian-Jun Yan; Feng Xu; Meng-Chao Wu; Yi-Qun Yan
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.

Authors:  Kiminori Uka; Hiroshi Aikata; Shintaro Takaki; Tomokazu Kawaoka; Hiromi Saneto; Daiki Miki; Shoichi Takahashi; Naoyuki Toyota; Katsuhide Ito; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

8.  Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.

Authors:  Kiminori Uka; Hiroshi Aikata; Shintaro Takaki; Daiki Miki; Tomokazu Kawaoka; Soo Cheol Jeong; Shoichi Takahashi; Naoyuki Toyota; Katsuhide Ito; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

9.  Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.

Authors:  Myron John Tong; Carlos Hsien; Joanna Jungeun Song; Jia Horng Kao; Hai-En Sun; Leeyen Hsu; Steven-Huy Han; Francisco Antonio Durazo; Sammy Saab; Lawrence Mitchell Blatt
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

10.  Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study.

Authors:  Hiroyuki Kirikoshi; Satoru Saito; Masato Yoneda; Koji Fujita; Hironori Mawatari; Takashi Uchiyama; Takuma Higurashi; Kento Imajo; Takashi Sakaguchi; Kazuhiro Atsukawa; Aya Sawabe; Akira Kanesaki; Hirokazu Takahashi; Yasunobu Abe; Masahiko Inamori; Noritoshi Kobayashi; Kensuke Kubota; Norio Ueno; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2009-04-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.